

Voacalginines AeE, new indole alkaloids from *Voacanga grandifolia*

by Idha Kusumawati

Submission date: 19-Apr-2021 04:05PM (UTC+0800)

Submission ID: 1563396266

File name: Jurnal_C-15.pdf (1.25M)

Word count: 5536

Character count: 23429



Voacalgines A–E, new indole alkaloids from *Voacanga grandifolia*



Yusuke Hirasawa^a, Hiroko Arai^a, Abdul Rahman^b, Idha Kusumawati^b,
Noor Cholies Zaini^b, Osamu Shirota^c, Hiroshi Morita^{a,*}

^a Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan

^b Faculty of Pharmacy, Airlangga University, Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia

^c Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki City, Kagawa 769-2193, Japan

ARTICLE INFO

Article history:

Received 29 July 2013

Received in revised form 24 October 2013

Accepted 26 October 2013

Available online 5 November 2013

Keywords:

Indole alkaloid

Voacanga grandifolia

Voacalgine A

Cytotoxicity

ABSTRACT


Five new indole alkaloids, voacalgines A–E (**1–5**) consisting of a C-mavacurine type of skeleton with 2,3-dihydroxybenzoate moiety, a macroline-type of skeleton, or a macroline-type of skeleton with C₆ unit, were isolated from the bark of *Voacanga grandifolia*. Their relative structures were determined by means of NMR data. Voacalgine A showed moderate cell growth inhibitory activities against HL-60 and HCT116 cells.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Voacanga grandifolia (Miq.) Rolfe is a member of the Apocynaceae family distributed in Indonesia and India, and is found mostly in Java.¹ The bark and leaves have been known to produce various skeletal alkaloids such as voacinol,² vobtusine,³ vobtusinelactone,⁴ and rhazine.⁵ In our search for bioactive alkaloids from

tropical plants,^{6–14} voacalgines A–E (**1–5**), five new indole alkaloids consisting of a C-mavacurine¹⁵ type of skeleton with fused benzoic acid moiety, a macroline¹⁶ type of skeleton, or a macroline-type of skeleton with another C₆ unit, have been isolated from the bark of *V. grandifolia*. In this paper, we describe the isolation and structure elucidation of **1–5** as well as their in vitro cell growth inhibitory activities against three human cell lines.



* Corresponding author. E-mail address: moritah@hoshi.ac.jp (H. Morita).

2. Results and discussion

2.1. Voacalgine A (1)

Voacalgine A (**1**) showed a molecular formula, $C_{27}H_{26}N_2O_6$, which was determined by HRESITOFMS [m/z 475.1842 ($M+H$)⁺, Δ -2.7 mmu]. IR absorption band was characteristic of carbonyl (1750 and 1670 cm^{-1}) and hydroxyl (3023 cm^{-1}) groups. ¹H and ¹³C NMR data (Table 1) suggested the presence of two sp³ quaternary carbons, four sp³ methylenes, three sp³ methines, two methyls, seven sp² methines, and nine sp² quaternary carbons. Among them, two sp³ methylenes (δ_C 48.8; δ_H 2.83 and 2.83, and δ_C 53.7; δ_H 3.11 and 4.34) and two sp³ methines (δ_C 52.8; δ_H 3.38, and δ_C 58.7; δ_H 4.67) were attached to the nitrogen atom, and one sp³ quaternary carbon (δ_C 104.7) was ascribed to that bearing both an oxygen and a nitrogen atoms.

Table 1

¹H (*J*, Hz) and ¹³C NMR data of voacalgine A (**1**) in CD₃OD at 300 K

Position	δ_H	δ_C
2		104.7
3	3.38 (1H, dd, 2.9, 2.9)	52.8
5	2.83 (2H, m)	48.8
6a	2.32 (1H, ddd, 15.2, 10.6, 6.7)	28.8
6b	2.55 (1H, br d, 15.2)	
7		49.8
8		136.4
9	6.79 (1H, dd, 7.8, 1.8)	123.6
10	6.81 (1H, ddd, 7.8, 7.8, 0.8)	122.0
11	7.10 (1H, ddd, 7.9, 7.8, 1.8)	128.8
12	6.39 (1H, d, 7.9)	111.5
13		146.6
14a	1.82 (1H, ddd, 13.6, 3.4, 3.4)	27.5
14b	2.77 (1H, ddd, 13.6, 3.3, 3.3)	
15	3.55 (1H, m)	32.6
16	4.67 (1H, d, 4.2)	58.7
17		171.3
18	1.65 (3H, dd, 6.8, 2.3)	12.6
19	5.50 (1H, dq, 1.7, 6.8)	122.0
20		135.3
21a	3.11 (1H, d, 12.8)	53.7
21b	4.34 (1H, br d, 12.8)	
1'		108.0
2'		152.9
3'		147.1
4'		128.5
5'	7.30 (1H, d, 8.3)	118.6
6'	7.26 (1H, d, 8.3)	123.1
1'-COOH		170.0
OMe	3.78 (3H, s)	52.9

The gross structure of **1** was deduced from extensive analyses of the two-dimensional NMR data, including the ¹H–¹H COSY, HMQC, and HMBC spectra in CD₃OD (Fig. 1). The ¹H–¹H COSY and HMQC spectra revealed connectivity of five partial structures **a** (C-5–C-6), **b** (C-9–C-12), **c** (C-3, C-14–C-16), **d** (C-18–C-19), and **e** (C-5'–C-6') as shown in Fig. 1.

HMBC cross-peaks of H₂-5 to C-3 and C-21, and H-3 to C-21 established the connections among C-3, C-5, and C-21 through N-4. The connectivity of partial structures **a**, **c**, and indoline ring (C-2, C-7–C-13 and N-1) was revealed by the HMBC correlations of H-9 and H₂-5 to C-7 (δ_C 49.8), and H-6b and H-14a to C-2 (δ_C 104.7). HMBC correlations from H₃-18 to C-20 and H-19 to C-15 and C-21 established the presence of piperidine ring (C-3, C-14–C-15, C-20–C-21, and N-4) with ethylidene side chain at C-20. HMBC correlations from H-16 to C-13, and H-16 and methoxy protons to C-17 indicated voacalgine A possessed C-mavacurine type skeleton. On the other hand, the presence of 2,3-dihydroxybenzoate including partial structure **e** was presumed from the HMBC correlations from H-5' to C-1' and C-3', and H-6' to C-2', C-4', and carboxyl carbon. In




Fig. 1. Selected 2D NMR correlations for voacalgine A (**1**).

addition, the connectivity between this moiety and indole alkaloid moiety at C-4' and C-7 was assigned by the HMBC correlations from H-6a to C-4' and H-5' to C-7. Moreover, the connectivity between C-3' (δ_C 147.1) and C-2 through an oxygen atom was elucidated by comparison of chemical shifts with bipleiophylline¹⁷ (δ_C 146.9 and δ_C 103.2, respectively). Thus, the gross structure of voacalgine A (**1**) was assigned to be a new indole alkaloid consisting of a C-mavacurine type of skeleton and 2,3-dihydroxybenzoic acid.

The relative stereochemistry of **1** was elucidated by the NOESY correlations. A 3,8-diazatricyclo[6.2.2.0^{4,9}]dodecane ring (C-2–C-7, C-14–C-16, C-20, C-21, N-1, and N-4) strongly required that both H-3 and H-15 were α -orientation, and α -orientation of benzoic acid moiety was supported by the NOESY correlations of H-6b/H-5' and H-6a/H-21b. An α -configuration of H-16 and *E*-configuration of double bond (C-19–C-20) were elucidated by the correlations of H-14b/H-16 and H-15/H₃-18, respectively (Fig. 2).




Fig. 2. Selected NOESY correlations for voacalgine A (**1**).

2.2. Voacalgine B (2)

Voacalgine B (**2**) showed a molecular formula, $C_{21}H_{24}N_2O_3$, which was determined by HRESITOFMS [m/z 353.1861 ($M+H$)⁺, Δ +0.1 mmu]. IR absorption band was characteristic of α,β -unsaturated ketone (1650 and 1620 cm^{-1}) and hydroxyl (3300 cm^{-1}) groups. ¹H and ¹³C NMR data (Table 2) suggested the presence of three sp³ methylenes, four sp³ methines, three methyls, four sp² methines, and seven sp² quaternary carbons. Among them, two sp³ methines (δ_C 57.5; δ_H 4.97, and δ_C 57.7; δ_H 3.98) and two methyls (δ_C 29.6; δ_H 3.68, and δ_C 40.6; δ_H 2.92) were attached to the nitrogen atom, and one sp³ methylene (δ_C 65.4; δ_H 4.27 and 4.35), one sp² methine (δ_C 160.5; δ_H 7.83), and one sp² quaternary carbon (δ_C 152.5) were ascribed to that bearing an oxygen atom.

Table 2
 ^1H (J , Hz) and ^{13}C NMR data of voacalgine B (**2**) in CD_3OD at 300 K^a

Position	δ_{H}	δ_{C}
2		128.9
3	4.97 (1H, br s)	57.5
5	3.98 (1H, d, 7.4)	57.7
6a	3.10 (1H, d, 18.0)	24.1
6b	3.49 (1H, dd, 18.0, 7.4)	
7		105.5
8		127.2
9	6.90 (1H, d, 2.3)	103.7
10		152.5
11	6.83 (1H, dd, 8.8, 2.3)	113.7
12	7.29 (1H, d, 8.8)	111.2
13		134.5
14a	1.99 (1H, dd, 11.8, 11.8)	31.4
14b	2.42 (1H, m)	
15	2.68 (1H, dt, 11.8, 6.0)	25.0
16	2.45 (1H, m)	39.0
17a	4.27 (1H, dd, 10.7, 10.7)	65.4
17b	4.35 (1H, dd, 10.7, 2.6)	
18	2.13 (3H, s)	25.0
19		198.3
20		119.5
21	7.83 (1H, s)	160.5
N(1)-Me	3.68 (3H, s)	29.6
N(4)-Me	2.92 (3H, s)	40.6

^a TFA salt.

The gross structure of **2** was deduced from extensive analyses of the two-dimensional NMR data, including the ^1H – ^1H COSY, HMQC, and HMBC spectra in CD_3OD (Fig. 3). The ^1H – ^1H COSY and HMQC spectra revealed connectivity of three partial structures **a** (C-3, C-14–C-17), **b** (C-5–C-6), and **c** (C-11–C-12) as shown in Fig. 3.




Fig. 3. Selected 2D NMR correlations for voacalgine B (**2**).

The presence of 5-hydroxy-*N*-methylindole ring was deduced by HMBC correlations of *N*(1)-Me to C-2 and C-13, H-9 to C-7 and C-13, H-12 to C-8 and oxygenated C-10, and H-11 to C-13. HMBC cross-peaks of *N*(4)-Me to C-3 and C-5 established the connection between C-3 and C-5 through *N*-4. The connection among indole ring and partial structures **a** and **b** was indicated by HMBC correlations of H-6 to C-7 and H-14 to C-2. HMBC correlations from H₃-18 to C-19 and C-20, and H-21 to C-15, C-17, and C-19 established the presence of 3,4-dihydro-2*H*-pyran ring (C-15–C-17, C-20–C-21 and O) with an acetyl group at C-20. Thus, the gross structure of voacalgine B (**2**) was assigned to be a new indole alkaloid with a hydroxyl group at C-10 of alstonerine.¹⁸

The relative stereochemistry of **2** was elucidated by the NOESY correlations. The correlations of H-14a/H-17a, H-16/H-15 and H-6a indicated the α -orientation of an *N*-methyl group at *N*-4 and the β -configuration of H-15 and H-16. Thus, the relative stereochemistry of **2** was assigned as shown in Fig. 4.

The CD spectrum of **2** showed a similar pattern to that of alstonerine.⁸ Thus, the absolute configurations of **2** were elucidated to be 3*S*, 5*S*, 15*R*, and 16*R*.




Fig. 4. Selected NOESY correlations for voacalgine B (**2**).

2.3. Voacalgine C (**3**)

Voacalgine C (**3**) showed a molecular formula, $\text{C}_{26}\text{H}_{34}\text{N}_2\text{O}_4$, which was determined by HRESITOFMS [m/z 439.2618 ($\text{M}+\text{H}$)⁺, Δ +2.1 mmu]. IR absorption band was characteristic of hydroxyl (3400 cm^{-1}) group. ^1H and ^{13}C NMR data (Table 3) suggested the presence of seven sp^3 methylenes, six sp^3 methines, two sp^3 quaternary carbons, three methyls, four sp^2 methines, and four sp^2 quaternary carbons. Among them, two sp^3 methines (δ_{C} 55.5; δ_{H} 4.44, and δ_{C} 58.0; δ_{H} 3.35) and two methyls (δ_{C} 29.3; δ_{H} 3.68, and δ_{C} 41.4; δ_{H} 2.59) were attached to the nitrogen atom, and an sp^3 methine (δ_{C} 70.5; δ_{H} 3.50), two sp^3 methylenes (δ_{C} 64.0; δ_{H} 3.82 and 4.00, and δ_{C} 62.7; δ_{H} 3.48 and 3.83), and two sp^3 quaternary carbon (δ_{C} 107.2 and 107.3) were ascribed to that bearing an oxygen atom.

Table 3
 ^1H (J , Hz) and ^{13}C NMR data of voacalgine C (**3**) in CD_3OD at 300 K^a

Position	δ_{H}	δ_{C}
2		131.0
3	4.44 (1H, br s)	55.5
5	3.35 (1H, m)	58.0
6a	2.70 (1H, br d, 16.1)	23.8
6b	3.34 (1H, m)	
7		106.9
8		127.2
9	7.46 (1H, d, 7.6)	119.0
10	7.06 (1H, dd, 7.6, 7.4)	120.3
11	7.17 (1H, dd, 7.4, 7.9)	122.7
12	7.36 (1H, d, 7.9)	110.1
13		139.0
14a	1.78 (1H, m)	32.3
14b	2.48 (1H, ddd, 14.7, 14.7, 3.5)	
15	1.78 (1H, m)	27.4
16	2.23 (1H, ddd, 10.0, 5.1, 5.1)	37.7
17a	3.82 (1H, m)	64.0
17b	4.00 (1H, dd, 11.9, 10.0)	
18	1.58 (3H, s)	26.0
19		107.3
20	2.07 (1H, dd, 11.8, 7.6)	44.2
21a	1.78 (1H, m)	38.8
21b	2.02 (1H, dd, 12.3, 12.3)	
22		107.2
23	3.50 (1H, br t, 3.0)	70.5
24a	1.62 (1H, m)	28.2
24b	1.97 (1H, dddd, 12.8, 12.6, 3.0, 3.0)	
25a	1.29 (1H, m)	20.9
25b	1.87 (1H, dddd, 12.6, 12.6, 12.4, 3.4, 3.4)	
26a	3.48 (1H, m)	62.7
26b	3.83 (1H, m)	
N(1)-Me	3.68 (3H, s)	29.3
N(4)-Me	2.59 (3H, s)	41.4

^a formic acid salt.

The gross structure of **3** was deduced from extensive analyses of the two-dimensional NMR data, including the ^1H - ^1H COSY, HMQC, and HMBC spectra in CD_3OD (Fig. 5). The ^1H - ^1H COSY and HMQC spectra revealed connectivity of four partial structures **a** (C-3, C-14–C-17, and C-20–C-21), **b** (C-5–C-6), **c** (C-9–C-12), and **d** (C-23–C-26) as shown in Fig. 5.




Fig. 5. Selected 2D NMR correlations for voacalgine C (**3**).

By analysis of HMBC spectrum as shown in Fig. 5, three partial structures **a–c** composed of a macroline-type skeleton at C-2–C-17. The HMBC correlations for H_3 -18 to C-19 (δ_{C} 107.3) and C-20 (δ_{C} 44.2), and H_2 -17 to C-19 indicated the presence of 2-methyltetrahydropyran ring (C-15–C-20 and O). Furthermore, correlations of H-20, H-24a, and H-26a to C-22 (δ_{C} 107.2) and H-21b to C-23 (δ_{C} 70.5) suggested the presence of tri-cyclic polyether structure on C-15–C-26. Thus, the gross structure of voacalgine C (**3**) was elucidated to be possessing a macroline-type skeleton with tetrahydropyran-2-spiro-2'-tetrahydrofuran ring as 25-deoxy form of macrodasine E.¹⁹

The relative stereochemistry of **3** was mainly elucidated by the NOESY correlations. In the 2-methyltetrahydropyran ring (C-15–C-20), the NOESY correlations of H_3 -18/H-14b, H-17b, and H-20, and a large 3J coupling constant (10.0 Hz) between H-16 and H-17b suggested that CH_3 -18 and H-20 were α -oriented and H-15 and H-16 were β -oriented. The correlations of H-5/H-17a and H-6a/H-16 indicated the α -orientation of an *N*-methyl group at N-4 (Fig. 6).

On the other hand, the NOESY correlations of H-24b/H-26b and large 3J coupling constants between H-24b/H-25b (12.4 Hz) and H-25b/H-26 (12.4 Hz) indicated that the tetrahydropyran ring (C-22–C-26) took chair conformation. And an α -oriented hydroxy group at C-23 was deduced from a small 3J coupling constant




Fig. 6. Selected NOESY correlations for voacalgine C (**3**).

(3.0 Hz) between H-23/H-24b. Finally, the relative configuration of a spiro carbon at C-22 was elucidated by the NOESY correlation of H_3 -18/H-26b.

The stable conformer corresponding to the axial orientation of OH-23 was generated after conformational searching by computer modeling (MMFF force field energy minimization) and the result was consistent with the coupling constants of H-23 (br t, 3.0 Hz).

2.4. Voacalgine D (**4**)

Voacalgine D (**4**) showed a molecular formula, $\text{C}_{26}\text{H}_{30}\text{N}_2\text{O}_4$, which was determined by HRESITOFMS [m/z 435.2299 ($\text{M}+\text{H}$)⁺, Δ +1.6 mmu]. IR absorption band was characteristic of α,β -unsaturated ketone (1670 cm^{-1}) and hydroxyl (3400 cm^{-1}) groups. By analysis of 1D and 2D NMR spectra (Table 4), voacalgine D possessed a macroline-type skeleton as well as voacalgine C.

Table 4

^1H (J , Hz) and ^{13}C NMR data of voacalgine D (**4**) in CD_3OD at 300 K^a

Position	δ_{H}	δ_{C}
2		132.3
3	4.20 (1H, br s)	55.6
5	3.13 (1H, m)	57.0
6a	2.54 (1H, d, 16.6)	23.6
6b	3.24 (1H, m)	
7		107.1
8		127.3
9	7.38 (1H, d, 7.6)	118.8
10	7.00 (1H, dd, 7.6, 7.4)	119.9
11	7.12 (1H, dd, 7.4, 7.9)	122.1
12	7.24 (1H, d, 7.9)	109.8
13		138.7
14a	1.68 (1H, m)	27.2
14b	2.87 (1H, m)	
15	1.65 (1H, m)	28.5
16	1.97 (1H, ddd, 11.8, 3.4, 3.4)	44.8
17a	3.46 (1H, m)	61.0
17b	4.49 (1H, dd, 11.7, 11.7)	
18	1.32 (3H, s)	28.4
19		98.3
20	2.21 (1H, ddd, 10.6, 5.3, 5.3)	43.6
21a	2.82 (1H, m)	37.9
21b	2.90 (1H, m)	
22	7.09 (1H, br d, 3.6)	190.6
23	6.54 (1H, dd, 3.6, 1.7)	153.9
24	7.66 (1H, dd, 1.7, 0.5)	119.2
25	3.44 (3H, s)	113.5
26	2.42 (3H, s)	148.7
N(1)-Me		29.1
N(4)-Me		41.5

^a Formic acid salt.

The HMBC correlations from H_3 -18 to C-19 (δ_{C} 98.3) and C-20 (δ_{C} 43.6), and H-17a to C-15 (δ_{C} 28.5) and C-19, and H-21a to C-15 indicated the presence of 2-hydroxy-2-methyltetrahydropyran ring (C-15–C-20 and O). And, the correlations of H-26/C-23 and C-24, and H-24/C-23 and 26 suggested the presence of a 2-furyl group on C-23–C-26. Furthermore, the connectivity of C-21 and C-23 through C-22 ketone was deduced from the HMBC correlation of H-21a to C-22 and the NOESY correlation of H-24/H-21a. Thus, the gross structure of voacalgine D (**4**) was assigned to be a new indole alkaloid consisting of a macroline-type skeleton with a 2-furyl group at C-21 (Fig. 7).

The relative stereochemistry of **4** was elucidated by the NOESY correlations. The correlations of H-14b/H-17b, H-15/H-16, H-16/H-20, and H-6a/H-16 indicated the α -orientation of an *N*-methyl group at N-4 and the β -configuration of H-15, H-16, and H-20. The




Fig. 7. Selected 2D NMR correlations for voacalgine D (4).

configuration of a methyl group at C-19 was assigned as equatorial by the NOESY correlation of H-20/H₃-18 and no correlation of H₃-18/H-17b (Fig. 8).




Fig. 8. Selected NOESY correlations for voacalgine D (4).

2.5. Voacalgine E (5)

Voacalgine E (5) showed molecular formula, C₂₆H₂₈N₂O₄, which was determined by HRESITOFMS [*m/z* 433.2144 (M+H)⁺, Δ +1.7 mmu]. IR absorption band was characteristic of ketone (1710 cm⁻¹) and α,β-unsaturated ketone (1670 cm⁻¹) groups. By analysis of 1D and 2D NMR spectra (Table 5), voacalgine E possessed a macroline-type skeleton and a 2-furyloyl group as well as voacalgine D.

The gross structure of 5 was deduced from extensive analyses of the two-dimensional NMR data. The ¹H–¹H COSY and HMQC spectra revealed connectivity of four partial structures a (C-3, C-14–C-17), b (C-5–C-6), c (C-9–C-12), and d (C-24–C-26) as shown in Fig. 9. Since, the left-half of the structure of voacalgine E in Fig. 9 showed similar HMBC correlations as well as voacalgine D (4), 5 was presumed to have a macroline-type skeleton. The HMBC correlations of H₂-17 to C-20 (δ_C 92.9), H₃-18 to C-19 (δ_C 214.9) and C-20, and H-15 to C-19 revealed the presence of 2-acetyltetrahydrofuran ring (C-15–C-20). On the other hand, the presence of a 2-furyloyl group was elucidated by the HMBC correlations from H-25 and H-26 to C-23 (δ_C 153.6), and H-24 to C-22 ketone (δ_C 186.6). And the connection of this moiety and C-20 through C-21 methylene was deduced by the HMBC correlations of

Table 5
¹H (J, Hz) and ¹³C NMR data of voacalgine E (5) in CD₃OD at 300 K^a

Position	δ _H	δ _C
2		126.8
3	5.09 (1H, br s)	56.0
5	4.01 (1H, br s)	55.6
6a	3.08 (1H, d, 17.6)	24.0
6b	3.42 (1H, dd, 17.6, 6.0)	
7		105.4
8		126.8
9	7.54 (1H, d, 7.7)	119.5
10	7.13 (1H, dd, 7.7, 7.6)	121.0
11	7.27 (1H, dd, 7.9, 7.6)	123.9
12	7.46 (1H, d, 7.9)	110.6
13		139.6
14a	2.28 (1H, ddd, 12.1, 11.8, 0.8)	27.6
14b	2.40 (1H, br d, 11.8)	
15	2.14 (1H, ddd, 12.1, 7.1, 5.9)	38.0
16	2.74 (1H, ddd, 8.2, 8.2, 7.1)	44.3
17a	4.23 (1H, dd, 9.9, 9.7)	69.4
17b	4.34 (1H, dd, 9.7, 9.4)	
18	2.24 (3H, s)	27.0
19		214.9
20		92.9
21a	3.36 (1H, m)	43.8
21b	3.49 (1H, m)	
22		186.6
23		153.6
24	7.36 (1H, br d, 3.4)	120.0
25	6.64 (1H, dd, 3.4, 1.2)	113.8
26	7.78 (1H, br s)	149.1
N(1)-Me	3.78 (3H, s)	29.7
N(4)-Me	2.94 (3H, s)	40.3

^a Formic acid salt.




Fig. 9. Selected 2D NMR correlations for voacalgine E (5).

H₂-21 to C-19, C-20, and C-22. Thus, the gross structure of voacalgine E was assigned to be a new indole alkaloid consisting of a macroline-type skeleton that E-ring is transformed to five-membered ring with a 2-furyloyl group at C-21 and an acetyl group at C-20.

The relative stereochemistry of 5 was elucidated by the NOESY correlations. The correlations of H-15/H-16, H-16/H₃-18, and H-6a/H-16 indicated the α-orientation of an N-methyl group at N-4 and the β-configuration of H-15, H-16, and an acetyl group (Fig. 10).

3. Plausible biogenetic pathway

A plausible biogenetic pathway of voacalgines A, D, and E (1, 4, and 5) with rare skeletons was proposed as shown in Fig. 11. Voacalgine A (1) is the second example combined with C-mavacurine type of skeleton (6) and 2,3-dihydroxybenzoic acid (7). Voacalgines D (4) and E (5) might be derived from the ring-opened form of alstonerine (8)²⁰ through introduction of C₆ unit²¹ to C-20 followed by cyclization.




Fig. 10. Selected NOESY correlations for voacalgine E (5).




Fig. 11. Plausible biogenetic pathway of voacalgines A (1), D (4), and E (5).

4. Conclusion

In this work, five new indole alkaloids, voacalgines A–E (1–5) were isolated from the bark of *V. grandifolia*. The structures and stereochemistry of 1–5 were elucidated by 2D NMR analysis.

Voacalgines A–E (1–5) were tested for cytotoxic activity against HL-60, HCT116, and MCF7 cell line. Voacalgine A only showed

moderate cell growth inhibitory activities against HL-60 and HCT116 cells (IC_{50} for 1: 12.1 μ M for HL-60, and 45.7 μ M for HCT116).

5. Experimental section

5.1. General experimental details

5.1.1. General methods. 1D and 2D NMR spectra were recorded on a Bruker AV700 spectrometer, and chemical shifts were referenced to the residual solvent peaks (δ_H 3.31 and δ_C 49.0 for methanol- d_4). Standard pulse sequences were employed for the 2D NMR experiments. 1H – 1H COSY, HOHAHA, and NOESY spectra were measured with spectral widths of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 t_1 increments. NOESY spectra in the phase-sensitive mode were measured with a mixing time of 800 ms. For HMQC spectra in the phase-sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1 K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

5.2. Material

The bark of *V. grandifolia* was collected at Purwodadi Botanical Garden, Indonesia in 2006. The botanical identification was made by Ms. Sri Wuryanti, Purwodadi Botanical Garden, Indonesia. A voucher specimen (no. AP070910) has been deposited in the herbarium at Purwodadi Botanical Garden, Pasuruan, Indonesia.

5.3. Extraction and isolation

The bark of *V. grandifolia* (444 g) was extracted with MeOH, the extract (32 g) was treated with 3% tartaric acid (pH 2) and then partitioned with EtOAc. The aqueous layer was treated with saturated Na₂CO₃ (aq) to pH 10 and extracted with CHCl₃ to give an alkaloidal fraction (4.3 g). The alkaloidal fraction was subjected to an amino SiO₂ column in hexane/EtOAc (1:0→0:1) and then CHCl₃/MeOH (1:0→0:1).

The CHCl₃/MeOH (50:1) eluted fraction was chromatographed over a SiO₂ column in CHCl₃/MeOH (1:0→0:1) and the CHCl₃/MeOH (50:1) eluted fraction was applied to an amino SiO₂ column in CHCl₃/MeOH (1:0→0:1) to afford voacalgine A (**1**, 4.0 mg, 0.0009%).

The CHCl₃/MeOH (1:0) eluted fraction of the first amino SiO₂ column was chromatographed over a SiO₂ column in CHCl₃/MeOH (1:0→0:1) and the CHCl₃/MeOH (50:1) eluted fraction was separated by an ODS HPLC (47% MeOH aq with 0.1% TFA, 2.0 mL/min, 254 nm) to afford voacalgine B (**2**, 3.7 mg, 0.0008%, t_R=15 min).

The hexane/EtOAc (2:1) eluted fraction of the first amino SiO₂ column was chromatographed over a SiO₂ column in CHCl₃/MeOH (1:0→0:1) and the CHCl₃/MeOH (80:1) eluted fraction was separated by an ODS HPLC (42% MeOH aq with 0.1% formic acid, 2.0 mL/min, 254 nm) to afford voacalgine E (**5**, 1.3 mg, 0.0003%, t_R=15 min), whereas the CHCl₃/MeOH (50:1) eluted fraction was chromatographed over an amino SiO₂ column in hexane/EtOAc (1:0→0:1) and the hexane/EtOAc (2:1) eluted fraction was separated by an ODS HPLC (40% MeOH aq with 0.1% formic acid, 2.0 mL/min, 254 nm) to afford voacalgine C (**3**, 0.9 mg, 0.0002%, t_R=20 min).

The CHCl₃/MeOH (100:1) eluted fraction of the first amino SiO₂ column was separated by an ODS HPLC (48% MeOH aq with 0.1% formic acid, 2.0 mL/min, 254 nm) to afford voacalgine D (**4**, 2.6 mg, 0.0006%, t_R=16 min).

5.4. Characterization of natural products

5.4.1. Voacalgine A (1). Brown amorphous solid; [α]_D²⁶ +110 (c 1.0, CHCl₃); IR (KBr) ν_{max} 3023, 1750, and 1670 cm⁻¹; UV (MeOH) λ_{max} 201 (ε 34,600), 229 (15,600), and 334 (3100) nm; ESIMS m/z 475 (M+H)⁺; HRESITOFMS m/z 475.1842 [(M+H)⁺, Δ -2.7 mmu, calcd for C₂₇H₂₇N₂O₆, 475.1869].

5.4.2. Voacalgine B (2). Brown amorphous solid; [α]_D²⁷ -67 (c 1.0, CHCl₃); IR (KBr) ν_{max} 3300, 1650, and 1620 cm⁻¹; UV (MeOH) λ_{max} 201 (ε 19,000) and 232 (19,900) nm; CD (MeOH) λ_{max} 301 (Δε -6.63), 259 (+7.68), 229 (-9.35), and 205 (+5.34); ESIMS m/z 353 (M+H)⁺; HRESITOFMS m/z 353.1861 [(M+H)⁺, Δ +0.1 mmu, calcd for C₂₁H₂₅N₂O₃, 353.1860].

5.4.3. Voacalgine C (3). Brown amorphous solid; [α]_D²² -22 (c 0.5, MeOH); IR (KBr) ν_{max} 3400 cm⁻¹; UV (MeOH) λ_{max} 201 (ε 12,100), 229 (18,600), and 336 (3800) nm; ESIMS m/z 439 (M+H)⁺; HRESITOFMS m/z 439.2618 [(M+H)⁺, Δ +2.1 mmu, calcd for C₂₆H₃₅N₂O₄, 439.2597].

5.4.4. Voacalgine D (4). Brown amorphous solid; [α]_D²⁴ -6 (c 1.0, MeOH); IR (KBr) ν_{max} 3400, 1670, and 1630 cm⁻¹; UV (MeOH) λ_{max} 229 (ε 30,400) and 273 (14,500) nm; ESIMS m/z 435 (M+H)⁺; HRESITOFMS m/z 435.2299 [(M+H)⁺, Δ +1.6 mmu, calcd for C₂₆H₃₁N₂O₄, 435.2234].

5.4.5. Voacalgine E (5). Brown amorphous solid; [α]_D²² -14 (c 0.5, MeOH); IR (KBr) ν_{max} 1710 and 1670 cm⁻¹; UV (MeOH) λ_{max} 201 (ε

14,900), 228 (20,400), and 374 (10,300) nm; ESIMS m/z 433 (M+H)⁺; HRESITOFMS m/z 433.2144 [(M+H)⁺, Δ +1.7 mmu, calcd for C₂₆H₂₉N₂O₄, 433.2127].

5.5. Cytotoxicity

HL-60, human promyelocytic leukemia cells were maintained in RPMI-1640 medium; MCF7, human breast adenocarcinoma; and HCT116, human colorectal adenocarcinoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) medium. Both growth media were supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. The cells (5×10³ cells/well) were cultured in Nunc disposable 96-well plates containing 90 μL of growth medium per well and were incubated at 37 °C in a humidified incubator of 5% CO₂. Ten microliters of serially diluted samples (50 μM, 25 μM, 12.5 μM, and 6.25 μM) were added to the cultures at 24 h of incubation. After 48 h of incubation with the samples, 15 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/mL) was added to each of the wells. The cultures were incubated for another 3 h before the cells supernatant are removed. After the removal of the cells supernatant, 50 μL of dimethyl sulfoxide (DMSO) was added to each well. The formed formazan crystal was dissolved by re-suspension by pipette. The optical density was measured using a microplate reader (Bio-Rad) at 550 nm with reference wavelength at 700 nm. In all experiments, three replicates were used. Cisplatin was used as positive control (IC₅₀: 0.87 μM for HL-60, 27.7 μM for MCF7, and 16.0 μM for HCT116).

Acknowledgements

This work was supported by Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science, The Open Research Center Project, and Takeda Science Foundation.

References and notes

- Biswas, R. C. *Sci. Cult.* **1970**, *36*, 552–554.
- Govindachari, T. R.; Sandhya, G.; Chandrasekharan, S.; Rajagopalan, K. *J. Chem. Soc., Chem. Commun.* **1987**, 1137–1138.
- Schuler, B. O. G.; Verbeek, A. A.; Warren, F. L. *J. Chem. Soc.* **1958**, 4776–4777.
- (a) Kunesch, N.; Das, B. C.; Poisson, J. *Bull. Soc. Chim. Fr.* **1970**, 4370–4375; (b) Rolland, Y.; Kunesch, N.; Poisson, J.; Hagaman, E. W.; Schell, F. M.; Wenkert, E. *J. Org. Chem.* **1976**, *41*, 3270–3275.
- Majumbar, P. L.; Dinda, B. N. *J. Indian Chem. Soc.* **1974**, *51*, 370.
- Yamasaki, F.; Machida, S.; Nakata, A.; Nugroho, A. E.; Hirasawa, Y.; Kaneda, T.; Shirota, O.; Hagane, N.; Sugizaki, T.; Morita, H. *J. Nat. Med.* **2013**, *67*, 212–216.
- Zaima, K.; Deguchi, J.; Matsuno, Y.; Kaneda, T.; Hirasawa, Y.; Morita, H. *J. Nat. Med.* **2013**, *67*, 196–201.
- Zaima, K.; Koga, I.; Iwasawa, N.; Hosoya, T.; Hirasawa, Y.; Kaneda, T.; Ismail, I. S.; Lajis, N. H.; Morita, H. *J. Nat. Med.* **2013**, *67*, 9–16.
- Deguchi, J.; Motegi, Y.; Nakata, A.; Hosoya, T.; Morita, H. *J. Nat. Med.* **2013**, *67*, 234–239.
- Nugroho, A. E.; Hirasawa, Y.; Wong, C. P.; Kaneda, T.; Hadi, A. H. A.; Shirota, O.; Ekasari, W.; Widayawaruyanti, A.; Morita, H. *J. Nat. Med.* **2012**, *66*, 350–353.
- Wong, C. P.; Shimada, M.; Nugroho, A. E.; Hirasawa, Y.; Kaneda, T.; Hadi, A. H. A.; Osamu, S.; Morita, H. *J. Nat. Med.* **2012**, *66*, 566–570.
- Zaima, K.; Takeyama, Y.; Koga, I.; Saito, A.; Tamamoto, H.; Abd. Azziz, S. S. S.; Mukhtar, M. R.; Awang, K.; Hadi, A. H. A.; Morita, H. *J. Nat. Med.* **2012**, *66*, 421–427.
- Morita, H.; Mori, R.; Deguchi, J.; Oshimi, S.; Hirasawa, Y.; Ekasari, W.; Widayawaruyanti, A.; Hadi, A. H. A. *J. Nat. Med.* **2012**, *66*, 571–575.
- Hosoya, T.; Nakata, A.; Yamasaki, F.; Abas, F.; Shaari, K.; Lajis, N. H.; Morita, H. *J. Nat. Med.* **2012**, *66*, 166–176.
- Calverley, M. J.; Banks, B. J.; Harley-Mason, J. *Tetrahedron Lett.* **1981**, *22*, 1635–1638.
- Ghedira, K.; Zeches-Hanrot, M.; Richard, B.; Massiot, G.; Le Men-Olivier, L.; Sevenet, T.; Goh, S. H. *Phytochemistry* **1988**, *27*, 3955–3962.
- Kam, T.-S.; Tan, S.-J.; Ng, S.-W.; Komiyama, K. *Org. Lett.* **2008**, *10*, 3749–3752.
- (a) Gilman, R. E. Ph.D. Thesis, University of Michigan, 1959. (b) Cook, J. M.; Le Quesne, P. W.; Elderfield, R. C. *Chem. Commun.* **1969**, 1306–1307.
- Tan, S.-J.; Robinson, W. T.; Komiyama, K.; Kam, T.-S. *Tetrahedron* **2011**, *67*, 3830–3838.
- Kam, T.-S.; Choo, Y.-M. *Tetrahedron* **2000**, *56*, 6143–6150.
- Kam, T.-S.; Choo, Y.-M. *Tetrahedron Lett.* **2003**, *44*, 8787–8789.

Voacalginines AeE, new indole alkaloids from *Voacanga grandifolia*

ORIGINALITY REPORT

15%

SIMILARITY INDEX

3%

INTERNET SOURCES

13%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

- 1** Wei-Guang Shan, Feng-Yun Ren, You-Min Ying, Cui-Ping Tong, Zha-Jun Zhan. " A new lycopodine alkaloid from ", *Journal of Chemical Research*, 2012
Publication 2%
- 2** www.mdpi.com
Internet Source 2%
- 3** Cao, Peng, Yong Liang, Xu Gao, Xiao-Ming Li, Zhen-Quan Song, and Guobiao Liang. "Monoterpenoid Indole Alkaloids from *Alstonia yunnanensis* and Their Cytotoxic and Anti-inflammatory Activities", *Molecules*, 2012.
Publication 2%
- 4** Kobayashi, Jun'ichi, Kazutaka Shimbo, Masaaki Sato, and Masashi Tsuda. "Amphidinolides H2–H5, G2, and G3, New Cytotoxic 26- and 27-Membered Macrolides from Dinoflagellate *Amphidinium* sp.", *The Journal of Organic Chemistry*, 2002.
Publication 1%

5

Kornsakulkarn, J.. "Dihydronaphthalenones from endophytic fungus *Fusarium* sp. BCC14842", *Tetrahedron*, 20110930

Publication

1 %

6

Ni-Ping Li, Miao Liu, Xiao-Jun Huang, Xue-Ying Gong, Wei Zhang, Min-Jing Cheng, Wen-Cai Ye, Lei Wang. "Gelsecorydines A-E, Five Gelsedine-Corynanthe Type Bisindole Alkaloids from the fruits of *Gelsemium elegans*", *The Journal of Organic Chemistry*, 2018

Publication

1 %

7

Zhang, Yao, Jun-Song Wang, Dan-Dan Wei, Yu-Cheng Gu, Xiao-Bing Wang, and Ling-Yi Kong. "Bioactive Terpenoids from the Fruits of *Aphanamixis grandifolia*", *Journal of Natural Products*, 2013.

Publication

<1 %

8

Afifa Bergaoui, Saoussen Hammami, Hichem Ben Jannet, Zine Mighr. " Echiofruzine, a novel naringenin diglycoside from growing in Tunisia ", *Natural Product Research*, 2007

Publication

<1 %

9

Shushni, Muftah A. M., Rajinder Singh, Renate Mentel, and Ulrike Lindequist. "Balticolid: A New 12-Membered Macrolide with Antiviral Activity from an Ascomycetous Fungus of Marine Origin", *Marine Drugs*, 2011.

<1 %

10

Dewa Gede Katja, Kindi Farabi, Desi Harneti, Tri Mayanti, Unang Supratman. "Cytotoxic Triterpenoid from the Stembark of *Chisocheton celebicus* (Meliaceae)", *Makara Journal of Science*, 2017

Publication

11

Morita, H.. "Antimitotic activity of glaupalol-related coumarins from *Glaucidium palmatum*", *Bioorganic & Medicinal Chemistry Letters*, 20040716

Publication

12

Fu, Yan-hui, Shun-lin Li, Shi-fei Li, Hong-ping He, Ying-tong Di, Yu Zhang, and Xiao-jiang Hao. "Cytotoxic eburnamine-aspidospermine type bisindole alkaloids from *Bousignonia mekongensis*", *Fitoterapia*, 2014.

Publication

13

Sheng-Jun Dai. "New norditerpenoid alkaloids from *Scutellaria barbata* with cytotoxic activities", *Natural Product Research*, 02/15/2011

Publication

14

Zhang, Feng, Chuan-Rui Zhang, Xia Tao, Jun Wang, Wan-Sheng Chen, and Jian-Min Yue. "Phragmalin-type limonoids with NF- κ B inhibition from *Chukrasia tabularis* var.

<1 %

<1 %

<1 %

<1 %

<1 %

velutina", Bioorganic & Medicinal Chemistry Letters, 2014.

Publication

15 Hong-Mei Niu. "Clerodane diterpenoids and prenylated flavonoids from *Dodonaea viscosa*", Journal of Asian Natural Products Research, 01/2010

Publication

16 Yu-Chia Chang, Nan-Fu Chen, Tsong-Long Hwang, Chung-Chih Tseng et al. "New marine sterols from an algal-bearing gorgonian coral *Pinnigorgia* sp", Steroids, 2016

Publication

17 "Ascochyatin, a Novel Bioactive Spirodioxynaphthalene Metabolite Produced by the Marine-derived Fungus, *Ascochyta* sp. NGB4", The Journal of Antibiotics, 03/2008

Publication

18 Claudio Campagnuolo, Ernesto Fattorusso, Orazio Taglialatela-Scafati. "Feroxosides A-B, two norlanostane tetraglycosides from the Caribbean sponge *Ectyoplasia ferox*", Tetrahedron, 2001

Publication

19 www.jbc.org

Internet Source

20 www.jove.com

Internet Source

21 Da Wang, Dan Su, Xian-Zhe Li, Dan Liu, Rong-Gang Xi, Hui-Yuan Gao, Xiao-Bo Wang. "Barrigenol triterpenes from the husks of *Xanthoceras sorbifolia* Bunge and their antitumor activities", RSC Advances, 2016
Publication

22 Ning Li. "Flavonoids from *Camptosorus sibiricus* Rupr.", Journal of Asian Natural Products Research, 1/1/2006
Publication

23 Zheng, Heng, Qiong Chen, Mengke Zhang, Yongji Lai, Liang Lei, Penghua Shu, Jinwen Zhang, Yongbo Xue, Zengwei Luo, Yan Li, Guangmin Yao, and Yonghui Zhang. "Cytotoxic ent-Kaurane Diterpenoids from *Salvia cavaleriei*", Journal of Natural Products, 2013.
Publication

24 Huang, S.Z.. "Daphnane-type diterpene esters with cytotoxic and anti-HIV-1 activities from *Daphne acutiloba* Rehd.", Phytochemistry, 201203
Publication

25 Iwashima, M.. "New marine steroids, yonarasterols, isolated from the Okinawan soft coral, *Clavularia viridis*", Steroids, 200003
Publication

26 Kinzo Watanabe, Makoto Iwashima, Kazuo Iguchi. "New bioactive marine steroids from the Okinawan soft coral *Clavularia viridis*", *Steroids*, 1996

Publication

<1 %

27 Li-Jie Zhang. "A new sterol glycoside from *Securidaca inappendiculata*", *Journal of Asian Natural Products Research*, 8/1/2005

Publication

<1 %

28 espace.library.uq.edu.au

Internet Source

<1 %

29 Heng Zheng, Qiong Chen, Mengke Zhang, Yongji Lai et al. " Cytotoxic -Kaurane Diterpenoids from ", *Journal of Natural Products*, 2013

Publication

<1 %

30 edoc.ub.uni-muenchen.de

Internet Source

<1 %

31 Cheng-Qin Liang, Yi-Ming Shi, Rong-Hua Luo, Xing-Yao Li et al. " Kadcoccitones A and B, Two New 6/6/5/5-Fused Tetracyclic Triterpenoids from ", *Organic Letters*, 2012

Publication

<1 %

32 Gan, Chew-Yan, Yun-Yee Low, Tadahiro Etoh, Masahiko Hayashi, Kanki Komiyama, and Toh-Seok Kam. "Leuconicines A–G and (–)-Eburnamaline, Biologically Active Strychnan

<1 %

and Eburnan Alkaloids from *Leuconotis*",
Journal of Natural Products, 2009.

Publication

33

Hongjie Zhang. "Antimalarial Agents from Plants II. Decursivine, A New Antimalarial Indole Alkaloid from *Rhaphidophora decursiva*", Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), 5/1/2002

Publication

<1 %

34

edepot.wur.nl

Internet Source

<1 %

35

tessera.spandidos-publications.com

Internet Source

<1 %

36

www.jstage.jst.go.jp

Internet Source

<1 %

37

Cheenpracha, Sarot, Thunwadee Ritthiwigrom, and Surat Laphookhieo. "Alstoniaphyllines A-C, Unusual Nitrogenous Derivatives from the Bark of *Alstonia macrophylla*", Journal of Natural Products, 2013.

Publication

<1 %

38

Shin-ichiro Kurimoto, Yu F. Sasaki, Yoshihiro Suyama, Naonobu Tanaka, Yoshiki Kashiwada, Takanori Nakamura. "Acylated Triterpene Saponins from the Stem Bark of *Acer nikoense*

<1 %

(Aceraceae)", CHEMICAL & PHARMACEUTICAL BULLETIN, 2016

Publication

Exclude quotes Off

Exclude matches Off

Exclude bibliography On

Voacalgines AeE, new indole alkaloids from *Voacanga grandifolia*

GRADEMARK REPORT

FINAL GRADE

/0

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7
